May 2010

Dear Colleague:

On behalf of the National Institute on Drug Abuse (NIDA) and the American Psychiatric Association (APA), it is our privilege to welcome you to a special research-based program track—Neurobiological Circuits of Addiction: Significance for Psychiatric Practice during the 163rd APA Annual Meeting.

There is little doubt we are at a crossroads when it comes to opportunities to improve or optimize our approach to drug abuse and addiction, both scientifically and politically. From the scientific point of view, NIDA is beginning to reap the benefits from several decades of stunning advances in neuroscience. The combined progress provides the most detailed picture yet of the underlying risks, mechanistic triggers and functional correlates of the disease of addiction at the molecular, neurochemical, circuit, brain system, and environmental levels. The opportunities that these scientific advances are opening up for us to develop more effective prevention and treatment strategies are unprecedented. Equally exciting is the shift in focus that the new administration has imparted to its national drug policy, and its professed commitment to energizing prevention and treatment efforts. This new climate is poised to create far more fertile ground for the rapid and effective implementation of scientific discovery.

NIDA’s special track will highlight a wide range of topics along this spectrum: from innovative technological advances such as the use of optogenetics and epigenetic research to elucidate the basic mechanisms underlying addictive behaviors to how the new knowledge is being translated into better prevention and treatments for drug use disorders. Special emphasis is given to sessions that touch upon the circuits in the brain that are involved with addiction but that are also disrupted in other mental illnesses. This new understanding of how mental illnesses disrupt brain function at the circuit level is giving new insights of why co-morbidity between drug use disorders and other psychiatric diseases is so frequent. Symposia and lectures will highlight areas critical to psychiatric practice including the unique issues facing military personnel and their families, the important clinical overlap of smoking with psychiatric disorders, an update on medications development for addiction, the commonalities between obesity and addiction, the potential therapeutic effects and abuse of cognitive enhancers, as well as novel approaches to stop the spread of HIV.

Scientific advances give hope to clinicians and their patients for better prevention and treatment of addiction and related mental illnesses. We are sure that the many activities planned for the NIDA track will reveal just how exciting the parallel and synergistic developments between science and practice are for our field.

Sincerely,

Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse

Alan F. Schatzberg, M.D.
President
American Psychiatric Association
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Planning Committee</td>
<td>4</td>
</tr>
<tr>
<td>Conference Information</td>
<td>6</td>
</tr>
<tr>
<td>Agenda</td>
<td>7</td>
</tr>
<tr>
<td>Saturday, May 22, 2010</td>
<td>7</td>
</tr>
<tr>
<td>Sunday, May 23, 2010</td>
<td>9</td>
</tr>
<tr>
<td>Monday, May 24, 2010</td>
<td>12</td>
</tr>
<tr>
<td>Tuesday, May 25, 2010</td>
<td>17</td>
</tr>
<tr>
<td>Wednesday, May 26, 2010</td>
<td>21</td>
</tr>
<tr>
<td>Notes</td>
<td>26</td>
</tr>
</tbody>
</table>
Planning Committee

**National Institute on Drug Abuse**

**NIDA Staff**

Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse

Timothy P. Condon, Ph.D.
Deputy Director
National Institute on Drug Abuse

Lucinda L. Miner, Ph.D.
Deputy Director
Office of Science Policy and Communications

Susan R. B. Weiss, Ph.D.
Chief
Science Policy Branch
Office of Science Policy and Communications

Will M. Aklin, Ph.D.
Program Official
Behavioral and Integrative Treatment Branch
Division of Clinical Neuroscience and Behavioral Research

Ruben D. Baler, Ph.D.
Health Scientist Administrator
Science Policy Branch
Office of Science Policy and Communications

James Bjork, Ph.D.
Program Official
Clinical Neuroscience Branch
Behavioral and Brain Development Branch
Division of Clinical Neuroscience and Behavioral Research

Cheryl Anne Boyce, Ph.D.
Chief
Behavioral and Brain Development Branch
Associate Director for Child and Adolescent Research
Division of Clinical Neuroscience and Behavioral Research

Wilson M. Compton, M.D., M.P.E.
Director
Division of Epidemiology, Services and Prevention Research

Richard A. Denisco, M.D., M.P.H
Medical Officer
Services Research Branch
Division of Epidemiology, Services and Prevention Research

Joseph Frascella, Ph.D.
Director
Division of Clinical Neuroscience and Behavioral Research

David A. Gorelick, M.D., Ph.D.
Intramural Research Program

Steven J. Grant, Ph.D.
Chief
Clinical Neuroscience Branch
Division of Clinical Neuroscience and Behavioral Research

Mary A. Kautz, Ph.D.
Program Official
Clinical Neuroscience Branch
Division of Clinical Neuroscience and Behavioral Research

Minda Lynch, Ph.D.
Chief
Behavioral and Cognitive Science Research Branch
Division of Basic Neuroscience and Behavioral Research
David J. McCann, Ph.D.
Acting Associate Director
Division of Pharmacotherapies and Medical Consequences of Drug Abuse

Ivan D. Montoya, M.D., M.P.H.
Acting Deputy Director
Division of Pharmacotherapies and Medical Consequences of Drug Abuse

Eve Reider, Ph.D.
Acting Chief
Prevention Research Branch
Division of Epidemiology, Services and Prevention Research

Jeffrey D. Schulden, M.D.
Medical Officer
Epidemiology Research Branch
Division of Epidemiology, Services and Prevention Research

Jane E. Smither
Constituent Liaison
Science Policy Branch
Office of Science Policy and Communications

Roger G. Sorensen, Ph.D., M.P.A.
Health Scientist Administrator
Functional Neuroscience Research Branch
Division of Basic Neuroscience and Behavioral Research

Cecelia M. Spitznas, Ph.D.
Program Official
Behavioral and Integrative Treatment Branch
Division of Clinical Neuroscience and Behavioral Research

Susan Volman, Ph.D.
Health Scientist Administrator
Behavioral and Cognitive Science Research Branch
Division of Basic Neuroscience and Behavioral Research

Cora Lee Wetherington, Ph.D.
Women and Sex/Gender Differences Research Coordinator and Health Scientist Administrator
Behavioral and Cognitive Science Research Branch
Division of Basic Neuroscience and Behavioral Research

American Psychiatric Association

Alan F. Schatzberg, M.D.
President
American Psychiatric Association (APA)

John A. Renner, Jr., M.D.
Associate Professor of Psychiatry
Boston University School of Medicine
Associate Chief of Psychiatry
VA Boston Healthcare System

Shelly F. Greenfield, M.D., M.P.H.
Associate Professor in Psychiatry
Harvard Medical School
Director
Clinical and Health Services Research
Division on Alcohol and Drug Abuse
McLean Hospital

Herbert D. Kleber, M.D.
Professor of Psychiatry and Director
Division on Substance Abuse
Columbia University

APA Staff

Deborah J. Hales, M.D.
Director
APA Division of Education

Darrel A. Regier, M.D., M.P.H.
Executive Director
American Psychiatric Institute for Research and Education
Director
APA Office of Research

Beatrice A. Eld
Associate Director
APA Department of Quality Improvement and Psychiatric Services

Joy Raether
Associate Director
Conference and Online Continuing Medical Education (CME)

Diane Runels
CME Course Administrator
Conference Information

This program book provides information about workshops, lectures, and symposia organized by the National Institute on Drug Abuse (NIDA). These activities are highlighted in blue.

NIDA has also included a number of other sessions from the American Psychiatric Association (APA) program based on scientific content that complements the theme. Sessions included in NIDA’s Research Track, as well as other sessions related to substance use and addiction, are also listed in the APA Annual Meeting Program Guide. Abstracts of all sessions are included on a CD provided to all attendees.

Invited Lectures

Nora D. Volkow, M.D., Director, NIDA, Frontiers of Science Lecture on *Addiction: Conflict Between Brain Circuits* on Tuesday, May 25, 2010, 9:00 a.m., Morial Convention Center, Hall A (Session #L12).

Karl Deisseroth, M.D., Ph.D., Frontiers of Science Lecture on *Optogenetics: Development and Application* on Monday, May 24, 2010, 11:00 a.m., Morial Convention Center, La Louisiane Room A/B (Session #L6).

A. Thomas McLellan, Ph.D., Lecture on *New Directions in Drug Policy: President Obama’s National Demand Reduction Priorities* on Tuesday, May 25, 2010, 1:30 p.m., Morial Convention Center, Room R02-05 (Session #L16).

Julio Montaner, M.D., Frontiers of Science Lecture on *Seek and Treat for Optimal Prevention of HIV/AIDS: STOP HIV/AIDS* on Wednesday, May 26, 2010, 11:00 a.m., Morial Convention Center, Room R02-05 (Session #L21).

Continuing Medical Education (CME)

The APA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 50 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Exhibit

A wide variety of materials are available at the NIDA exhibit, Booth 1033, Halls B-D, Morial Convention Center. Please allow time to visit the NIDA exhibit to learn more about drug abuse.

Website

Information about NIDA research, programs, and events is accessible through NIDA’s website at www.drugabuse.gov.
### Agenda

#### Saturday, May 22, 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>Session (Session #S3)</th>
<th>Location</th>
<th>Co-Chairs</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 9:00 a.m. – 11:00 a.m. | **Symposium** *Smoking and Psychiatric Disorders: Clues About Causal Pathways and Innovative Treatment Approaches* | Morial Convention Center, Room 223 | Jeffrey D. Schulden, M.D.  
National Institute on Drug Abuse  
Wilson M. Compton, M.D., M.P.E.  
National Institute on Drug Abuse | Lisa Dierker, Ph.D.  
Wesleyan University  
*Psychiatric Disorders as Signals of Sensitivity for Nicotine Dependence*  
Robert Freedman, M.D.  
University of Colorado  
*Nicotine Receptors and Their Genes in Psychosis*  
Douglas M. Ziedonis, M.D.  
University of Massachusetts Medical School  
*Integrating Tobacco Dependence Treatment Into Mental Health and Addiction Treatment* |

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Session (Session #S29)</th>
<th>Location</th>
<th>Co-Chairs</th>
<th>(Session continued on next page)</th>
</tr>
</thead>
</table>
| 2:00 p.m. – 5:00 p.m. | **Symposium** *Executive Function as a Brain System for Self-Control: The Neurocircuitry of Psychiatric Disorders and Addiction* | Morial Convention Center, Room 355 | Mary A. Kautz, Ph.D.  
National Institute on Drug Abuse  
Minda Lynch, Ph.D.  
National Institute on Drug Abuse | Shaded entries indicate NIDA-organized sessions. |
Day: Saturday, May 22

**Symposium (Session #S30)**

**Addiction Research, Prevention, and Treatment in the United States and France: Vive la Difference!**

Morial Convention Center, Room 356/357

**Chair:** John A. Talbott, M.D.
University of Maryland School of Medicine

**Speakers:**
- Nora D. Volkow, M.D.
  Director, National Institute on Drug Abuse
  *Progress in Addiction Research*

- Marc-Antoine Crocq, M.D.
  Centre Hospitalier
  *Patterns of Addiction in High School and University Students*

*(Session continued on next page)*
(Session continued from previous page)

Speakers: Joshua Sharfstein, M.D.
U.S. Food and Drug Administration (FDA)
*The FDA and Tobacco Regulation*

Renaud de Beaurepaire, M.D.
Paul Guiraud Hospital
*Do Psychiatric Patients Smoke to Self-Medicate, or Is It for Other Reasons?*

David Oslin, M.D.
University of Pennsylvania Medical Center
*The State of Treatment of Addictive Disorders in the United States*

Amine Benyamina, M.D.
Paul Brousse University Hospital
*Organization and Health Care Networks for Cannabis Treatment in France*

Sunday, May 23, 2010

9:00 a.m. – 12:00 p.m. Symposium (Session #S35)

**Sex/Gender Differences and Women-Specific Issues in Drug Abuse: Predicting and Improving Treatment Outcomes**
Morial Convention Center, Room 353

Co-Chairs: Cora Lee Wetherington, Ph.D.
National Institute on Drug Abuse

Shelly Greenfield, M.D., M.P.H.
Harvard Medical School

Speakers: Kathleen Brady, M.D., Ph.D.
Medical University of South Carolina
*Gender Differences in Psychiatric Comorbidity With Substance Use Disorder: Implications for “Telescoping” and Treatment*

(Session continued on next page)
(Session continued from previous page)

Speakers:
Rajita Sinha, Ph.D.
Yale University School of Medicine
*Significant Role of Sex-Based Biology in Predicting Relapse and Clinical Outcomes in Drug Abuse*

Shelly Greenfield, M.D., M.P.H.
Harvard Medical School
*Women-Focused Treatment for Substance Use Disorders: Results From the Women's Recovery Group Study*

Denise Hien, Ph.D.
Columbia University
*Substance-Abusing Women With PTSD: How Best to Treat?*

Theresa Winhusen, Ph.D.
University of Cincinnati College of Medicine
*The Use of Motivational Enhancement Therapy and Vouchers to Improve Treatment Utilization and Outcome in Pregnant Substance Users*

---

1:30 p.m. – 3:00 p.m.  Workshop (Session #W56)

**Maintenance Treatment for Opiate Dependence: Terminable or Interminable?**
Morial Convention Center, Room 346

Co-Chairs:  Ivan D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Herbert D. Kleber, M.D.
Columbia University

Speakers:  Steven Batki, M.D.
University of California, San Francisco

Robert Schwartz, M.D.
Friends Research Institute

Kenzie Preston, Ph.D.
National Institute on Drug Abuse

Shaded entries indicate NIDA-organized sessions.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 5:00 p.m.</td>
<td>Symposium (Session #S36) Treating Chronic Pain and Co-occurring Addiction in Substance Abuse Patients Morial Convention Center, Room 347</td>
</tr>
</tbody>
</table>

**Co-Chairs:**
- Richard A. Denisco, M.D., M.P.H.
  National Institute on Drug Abuse
- Will M. Aklin, Ph.D.
  National Institute on Drug Abuse

**Speakers:**
- Ian R. Carroll, M.D., M.P.H.
  Stanford University
  *Why Do Some Patients Have Persistent Pain and Persistent Opioid Use Following Surgery: An Inception Cohort Study?*
- Steve Passik, Ph.D.
  Memorial Sloan-Kettering Cancer Center
  *Clinical Aspects of Risk Management in Opioid Therapy*
- Declan T. Barry, Ph.D.
  Yale University
  *Behavioral Treatment for Co-occurring Chronic Pain and Opioid Addiction*
- Roger D. Weiss, M.D.
  Harvard University
  *Results of the Prescription Opioid Addiction Treatment Study: A Multisite Trial of the NIDA Clinical Trials Network*
- Sean Mackey, M.D., Ph.D.
  Stanford University School of Medicine
  *Overview of the Treatment of Acute and Chronic Pain in the Patient With a History of Addiction*
9:00 a.m. – 12:00 p.m.  Symposium (Session #S42)
**Update on Medications Development: Promising New Treatments for Drug Addiction**
Morial Convention Center, Room 356/357

**Co-Chairs:**  Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

David J. McCann, Ph.D.
National Institute on Drug Abuse

**Speakers:**  Charles O'Brien, M.D., Ph.D.
University of Pennsylvania School of Medicine
*Modafinil as a Novel Medication in the Treatment of Cocaine Addiction*

Kathleen Brady, M.D., Ph.D.
Medical University of South Carolina
*D-Cycloserine in the Treatment of Cocaine and Nicotine Dependence*

David J. McCann, Ph.D.
National Institute on Drug Abuse
*Bupropion for the Treatment of Methamphetamine Addiction*

Frances R. Levin, M.D.
Columbia University
*Dronabinol for Cannabis Addiction Treatment*

Raafat Fahim, Ph.D.
Nabi Biopharmaceuticals
*NicVAX: An Innovative Vaccine Treatment for Nicotine Addiction*

**Discussant:**  Herbert D. Kleber, M.D.
Columbia University
Monday, May 24

11:00 a.m. – 12:30 p.m.  
**Frontiers of Science Lecture (Session #L6)**  
**Optogenetics: Development and Application**  
Morial Convention Center, La Louisiane Room A/B  

**Speaker:** Karl Deisseroth, M.D., Ph.D.  
Stanford University

---

2:00 p.m. – 5:00 p.m.  
**Presidential Symposium (Session #PS03)**  
**Can Basic and Translational Neuroscience Improve Treatment in Psychiatry?**  
Morial Convention Center, Room 220-222  

**Co-Chairs:** Alan F. Schatzberg, M.D.  
President, American Psychiatric Association  
Stanford University  
Karl Deisseroth, M.D., Ph.D.  
Stanford University  

**Speakers:**  
Kerry Ressler, M.D., Ph.D.  
Emory University  
*Translational Studies in Genetics: Genetic Tools in Animal Models to Understand Heritable Risk Factors in Depression and Posttraumatic Stress Disorder*  
Amit Etkin, M.D., Ph.D.  
Stanford University  
*Emotion Regulation: Toward a Neurobiological Understanding of Psychotherapy*  
Karl Deisseroth, M.D., Ph.D.  
Stanford University  
*Optogenetics: Development and Application*  
Vikaas Sohal, M.D., Ph.D.  
Stanford University  
*Using Optogenetic Tools and Information Theory to Elucidate Prefrontal Microcircuit Dysfunction in Schizophrenia*
Monday, May 24

2:00 p.m. – 5:00 p.m.

Symposium (Session #S52)

**Innovations in Integrated Treatment of Substance Use and Psychiatric Disorders**

Morial Convention Center, Room 338/339

Co-Chairs: Ivan D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Wilson M. Compton, M.D., M.P.E.
National Institute on Drug Abuse

Speakers: Paul Rohde, Ph.D.
Oregon Research Institute

*Integrated Treatment of Depression and Substance Use Disorders in Adolescents*

Kathleen Brady, M.D., Ph.D.
Medical University of South Carolina

*Posttraumatic Stress Disorder and Drug Abuse: Etiology and Treatment Linkages*

Roger D. Weiss, M.D.
Harvard University

*Integrated Group Therapy for Patients With Co-occurring Bipolar Disorder and Substance Use Disorder*

Edward V. Nunes, M.D.
Columbia University

*Advances in Pharmacotherapy for Comorbid Depression and Addictions*

Alan I. Green, M.D.
Dartmouth University

*Treatment of Cannabis Use Disorder in Patients With Schizophrenia*

Discussant: Stanley Sacks, Ph.D.
Center for the Integration of Research and Practice
Monday, May 24

2:00 p.m. – 5:00 p.m. Symposium (Session #S54)
**Substance Related Disorders in DSM-5: Progress Report**
Morial Convention Center, Room 342

Co-Chairs: Charles O’Brien, M.D., Ph.D.
University of Pennsylvania School of Medicine

Deborah S. Hasin, Ph.D.
Columbia University

Speakers: Marc Schuckit, M.D.
University of California, San Diego
*The Search for Specific Criteria: A Report From the Criterion Subcommittee*

Deborah S. Hasin, Ph.D.
Columbia University
*Abuse and Dependence: Combining the Disorders Into a Single Category*

Nancy M. Petry, Ph.D.
University of Connecticut Health Center
*Non-Substance Related Addictions: Their Place in DSM-V*

Wilson M. Compton, M.D., M.P.H.
National Institute on Drug Abuse
*Terminology of Substance Use Disorders for DSM-V*

Thomas J. Crowley, M.D.
University of Colorado, Denver
*Severity of Substance Use Disorders*

2:00 p.m. – 5:00 p.m. Symposium (Session #S59)
**Neurobiology of Obesity: Why We Can Get Too Motivated to Eat**
Morial Convention Center, Room 356/357

Co-Chairs: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

Joseph Frascella, Ph.D.
National Institute on Drug Abuse

(Session continued on next page)
(Session continued from previous page)

Speakers: David A. Kessler, M.D.
University of California, San Francisco
Overeating and Obesity: Any End in Sight to Our “Addiction” to Food?

Hans-Rudolf Berthoud, Ph.D.
Pennington Biomedical Research Center, Louisiana State University
Central Control of Food Intake: Appetite Control and the Reward-Driven Brain

Serge Ahmed, Ph.D.
University of Bordeaux
Sweetness as a Super Reward: Comparison With Cocaine and Heroin

Cary R. Savage, Ph.D.
University of Kansas Medical Center
Functional Neuroimaging in Obese and Healthy Weight Groups: Food Motivation and Monetary Reward

Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse
Neurocircuitry of Addiction and Obesity

Discussant: Nora D. Volkow, M.D.

3:30 p.m. – 5:00 p.m. Scientific and Clinical Reports (Session #SCR13)
Addictive Behavior
Morial Convention Center, Room 348/349

Speakers: Deepak Prabhakar, M.D., M.P.H.
Wayne State University-Detroit Medical Center
Disparities in Substance Abuse Prevalence: Is It Time to Strategize and Refocus?

(Session continued on next page)
(Session continued from previous page)

Speakers: Pinhas Dannon, M.D.
Beer Yaakov Mental Health Hospital
*Pathological Gambling: An Impulse Control Disorder?*
*Measurement of Impulsivity Through Neurocognitive Tests*

David A. Gorelick, M.D., Ph.D.
National Institute on Drug Abuse
*Quitting Cannabis Use Without Formal Treatment in Adults*

---

**Tuesday, May 25, 2010**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9:00 a.m. – 10:30 a.m. | Frontiers of Science Lecture (Session #L12)  
**Addiction: Conflict Between Brain Circuits**  
Morial Convention Center, Hall A |
| Speaker:         | Nora D. Volkow, M.D.  
Director, National Institute on Drug Abuse |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9:00 a.m. – 11:00 a.m. | Symposium (Session #S63)  
**Adolescent Potential: Exploring the Developing Brain and Understanding Pathways of Addiction**  
Morial Convention Center, Room 238/239 |
| Co-Chairs:       | Cheryl Anne Boyce, Ph.D.  
National Institute on Drug Abuse  
Joseph Frascella, Ph.D.  
National Institute on Drug Abuse |
| Speakers:        | Linda Spear, Ph.D.  
State University of New York at Binghamton  
*The Developing Brain, Adolescence, and Alcohol/Drug Use: An Evolutionary Approach* |

(Session continued on next page)
(Session continued from previous page)

Speakers: Jay N. Giedd, M.D.
National Institute of Mental Health
The Teen Brain: Insights From Neuroimaging

Beatriz Luna, Ph.D.
University of Pittsburgh Medical Center
Vulnerabilities in Adolescent Decision Making: Neuroimaging
Evidence of Immaturities in Cognitive Control, Reward Processing, and Brain Connectivity

Susan F. Tapert, Ph.D.
University of California, San Diego
Brain Functioning in Adolescent Substance Using Boys and Girls

9:00 a.m. – 12:00 p.m. Symposium (Session #S68)
Reward Neurocircuitry in Substance Dependence and Other Psychiatric Disorders: What Does Brain Research Tell Us?
Morial Convention Center, Room 352

Co-Chairs: Susan Volman, Ph.D.
National Institute on Drug Abuse

James Bjork, Ph.D.
National Institute on Drug Abuse

Speakers: Susan R. Sesack, Ph.D.
University of Pittsburgh
Reward Neurocircuitry in Preclinical Models: Foundations and Alterations With Drug Use

Mauricio Delgado, Ph.D.
Rutgers University
Functional Neuroimaging of Neural Circuits Regulating Aversive Emotional Reactions and Expectations of Reward

(Session continued on next page)
(Session continued from previous page)

Speakers: Wayne C. Drevets, M.D.
Oklahoma University College of Medicine
*Neuroimaging Studies of Reward Processing in Major Depressive Disorder*

Elliot Hong, M.D.
Maryland Psychiatric Research Center
*Association of Nicotine Addiction and Nicotine’s Actions With Separate Cingulate Cortex Functional Circuits*

James M. Swanson, Ph.D.
University of California Irvine School of Medicine
*PET Evaluation of Neurocircuitry Related to Etiology and Treatment of ADHD*

11:00 a.m. – 12:30 p.m. Small Interactive Session (Session #SI15)

**Addiction and the Brain**
*(Limited to Resident Members of APA on a First-Come/First-Served Basis)*

Morial Convention Center, Room 237

Speaker: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

1:30 p.m. – 3:00 p.m. Lecture (Session #L16)

**New Directions in Drug Policy: President Obama’s National Demand Reduction Priorities**

Morial Convention Center, Room R02-05

Speaker: A. Thomas McLellan, Ph.D.
Deputy Director, White House Office of National Drug Control Policy
2:00 p.m. – 5:00 p.m. Advances in Series (Session #A07)

Advances in Substance Abuse Treatment
Morial Convention Center, Room 353-355

Co-Chairs: Marc Galanter, M.D.
New York University School of Medicine

Herbert D. Kleber, M.D.
Columbia University

Speakers: John A. Renner, Jr., M.D.
Boston University School of Medicine
The Use of Buprenorphine in the Treatment of Opioid Dependence

Hendree E. Jones, M.D.
Johns Hopkins Bayview Medical Center
The Treatment of Perinatal Addiction

Mark S. Gold, M.D.
McKnight Brain Institute, University of Florida
Treatment of Marijuana Abuse and Dependence

Richard K. Ries, M.D.
Harborview Medical Center
Treatment of the Dually Diagnosed

Harrison G. Pope, Jr., M.D.
McLean Hospital
Treatment of Anabolic-Androgenic Steroid Abuse

2:00 p.m. – 5:00 p.m. Symposium (Session #S79)

The Challenge of Cognitive Enhancers in Medicine
Morial Convention Center, Room 338/339

Co-Chairs: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

Ruben D. Baler, Ph.D.
National Institute on Drug Abuse

(Session continued on next page)
(Session continued from previous page)

Speakers: Herbert Y. Meltzer, M.D. Vanderbilt University
5-HT Receptors as Targets for Cognitive Enhancement in Schizophrenia

Nora D. Volkow, M.D. Director, National Institute on Drug Abuse
ADHD Treatment, Comorbidity With SUDs, and COGS-Related Diversion

Charles Dackis, M.D. University of Pennsylvania
Modafinil’s Abuse Potential and Possible Role in Cocaine Dependence

James M. Ellison, M.D., M.P.H. Harvard Medical School
Nonimpaired Elders, Cognitive Enhancers, and the Boundaries of Usual and Customary Practice

Barbara Sahakian, M.D. University of Cambridge
Pharmacological Cognitive Enhancement in Neuropsychiatric Disorders and in Healthy People

Wednesday, May 26, 2010

9:00 a.m. – 12:00 p.m. Symposium (Session #S86)
How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders
Morial Convention Center, Room 224

Co-Chairs: Roger G. Sorensen, Ph.D., M.P.A.
National Institute on Drug Abuse

Steven J. Grant, Ph.D.
National Institute on Drug Abuse

(Session continued on next page)
(Session continued from previous page)

Speakers: Mark A. Gluck, Ph.D.
Rutgers University
Selective Impairments in Reward vs. Punishment Learning in Psychiatric Disorders

A. David Redish, Ph.D.
University of Minnesota
Addiction as Dysfunction in Learning-and-Memory-Based Decision Systems: Multiple Potential Failure Points Leading to Multiple Addiction Endophenotypes

Anna Rose Childress, Ph.D.
University of Pennsylvania School of Medicine
Impaired Modulation of Learned Motivational Responses to Cues: Common Core Dysfunctions in Addiction—and in PTSD

Peter W. Kalivas, Ph.D.
Medical University of South Carolina
Neuroplasticity in Prefrontal Regulation of the Basal Ganglia Underlies Vulnerability to Relapse

Kevin S. LaBar, Ph.D.
Duke University
Emotional Influences on Memory Circuits in Posttraumatic Stress Disorder and Healthy Adults

9:00 a.m. – 12:00 p.m. Symposium (Session #S92)
Update on Cannabis Use Disorders
Morial Convention Center, Room 340/341

Chair: David A. Gorelick, M.D., Ph.D.
National Institute on Drug Abuse

Speakers: Deborah S. Hasin, Ph.D.
Columbia University
Marijuana Abuse and Dependence in the General Population: Risk Factors, Symptom Structure, and Axis I and Axis II Comorbidity Effects on Persistence

(Session continued on next page)
(Session continued from previous page)

Speakers: Aviv M. Weinstein, B.S.C.
Hadassah Medical Organization
Neurobiology and Brain Imaging of Cannabis Dependence

Alan Budney, Ph.D.
University of Arkansas
Advances in the Development of Behavioral Treatments for Cannabis Use Disorders

Margaret Haney, Ph.D.
Columbia University
Advances in the Development of Pharmacological Treatments for Cannabis Use Disorders

David A. Gorelick, M.D., Ph.D.
National Institute on Drug Abuse
Medical and Psychiatric Effects Associated With Cannabis Use

9:00 a.m. - 12:00 p.m. Symposium (Session #S94)
Choosing the Right Treatment for Substance Abuse
Morial Convention Center, Rooms 346/347

Chair: Herbert D. Kleber, M.D.
Columbia University

Speakers: Adam Bisaga, M.D.
Columbia University
Choosing the Right Treatment for Cocaine Dependence

Frances R. Levin, M.D.
Columbia University
Choosing Treatments for Cannabis Dependence: What are the Options?

(Session continued on next page)
Wednesday, May 26

(Session continued from previous page)

Speakers: Edward V. Nunes, M.D.
Columbia University
Principles of Combining Medications and Psychosocial Interventions in the Treatment of Substance Dependence

Maria A. Sullivan, M.D., Ph.D.
Columbia University
Pain and Addiction: Substance Use Disorders in the Context of Opioid Therapy

9:00 a.m. – 12:00 p.m. Symposium (Session #S98)
Novel Tools for Preventing and Treating Substance Use and Comorbidities in the Military and Returning Veterans
Morial Convention Center, Room 356/357

Co-Chairs: Cecelia M. Spitznas, Ph.D.
National Institute on Drug Abuse

Eve Reider, Ph.D.
National Institute on Drug Abuse

Speakers: Tyler C. Smith, Ph.D., M.S.
Naval Health Research Center
Understanding Long-Term Tobacco and Alcohol Use and Comorbid Mental Health Symptoms in Military Service Members and Veterans: The Millennium Cohort Study

Magdalena R. Naylor, M.D., Ph.D.
University of Vermont College of Medicine
Automated Interactive Voice Response as a Therapeutic Tool for Chronic Pain Reduction and Opioid Medication Use Decrease

Barbara Rothbaum, Ph.D.
Emory School of Medicine
Virtual Reality and D-Cycloserine for Exposure-Based Therapy

(Session continued on next page)
### Frontiers of Science Lecture (Session #L21)

#### Seek and Treat for Optimal Prevention of HIV/AIDS: STOP HIV/AIDS

Morial Convention Center, Room R02-05

**Speaker:** Julio Montaner, M.D.

University of British Columbia